Munich EUR

Novo Nordisk A/S (NOV.MU)

51.72

-3.91

(-7.03%)

At close: 8:50:45 PM GMT+2

How Eli Lilly's GLP-1 pill could transform the weight-loss space

Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ongoing weight-loss pill trial. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination with Host Josh Lipton, Unlimited co-founder, CEO, and chief investment officer Bob Elliott, and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to explain why the test results sent the pharmaceutical stock soaring. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 3 hours ago

LLY

NONOF

NVO
Eli Lilly stock soars on positive weight-loss pill results

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & Hers Health (HIMS) stocks are falling on the news. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 9 hours ago

HIMS

LLY

NONOF
Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill

Eli Lilly stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds.

Investor's Business Daily 3 hours ago

VKTX

LLY

NONOF
Novo Nordisk downgraded by BMO as Eli Lilly gains ground in weight-loss drug race

Investing.com -- BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is being overtaken by rival Eli Lilly’s rapidly advancing pipeline.

Investing.com 5 hours ago

NVO

LLY
Novo Nordisk Stock Drops on Eli Lilly Oral Weight-Loss Drug Success, Downgrade

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's stock.

Investopedia 6 hours ago

NVO

LLY
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

Motley Fool 7 hours ago

LLY

NVO

VKTX
Novo Nordisk shares slump following Eli Lilly’s weight-loss pill success

Investing.com -- Novo Nordisk A/S (NYSE:NVO) shares fell as much as 8% in Thursday trading after news emerged about a competitor’s successful drug trial.

Investing.com 9 hours ago

NVO

LLY
Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch

In March this year, U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in India, which is expected to have the second-largest population of overweight or obese people by ...

Benzinga 13 hours ago

LLY

NVO
“I Am a Buyer”: Jim Cramer Backs Novo Nordisk (NVO) After Its Sharp Decline

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer discussed recently. On Friday, Mad Money host Jim Cramer addressed growing concerns in the market as tensions between the […]

Insider Monkey 21 hours ago

NVO
Novo Nordisk A/S (NVO): A Bull Case Theory

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading at $64.49 as of April 15th. NVO’s trailing and forward P/E were 18.76 and 15.41 respectively according to Yahoo Finance. Novo Nordisk, a dominant […]

Insider Monkey yesterday

NVO

LLY
The GLP-1 drug shortage is over. What’s next for the compounders?

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.

Pharmaceutical Technology yesterday

NVO

LLY
Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?

Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.

Zacks yesterday

LLY

NVO
Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts

On Monday, Novo Nordisk A/S (NYSE:NVO) said it had become aware of several hundred units of Ozempic (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the U.S. The seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits 51746517. Lot number PAR0362 is an authentic lot number. Only when the lot number is coupled with the eight digits 51746517 it is counterfeit and should not be used. Als

Benzinga 2 days ago

NVO
Is Novo Nordisk A/S (NVO) the Best Pharma Stock to Buy for Long Term Growth?

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big American […]

Insider Monkey 2 days ago

NVO
Pfizer Halts Obesity Pill Development Amid Safety Concerns

PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.

Zacks 2 days ago

PFE

LLY

NVO
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the

TipRanks 2 days ago

NONOF

NVO

LLY
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

Zacks 2 days ago

PFE

NVO

VKTX
Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries

HYDERABAD (Reuters) -The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its availability, with some Indian doctors fielding hundreds of calls about the medicine, according to a Reuters survey. The survey of 18 doctors, patients and weight-loss clinic operators follows the U.S. drugmaker's market entry ahead of Danish obesity drug rival Novo Nordisk into a nation expected to have the second-largest population of overweight or obese people by 2050. "Since the launch of Mounjaro, we have seen a remarkable increase in customer interest," said Suryansh Kumar, founder of Delhi-based weight management services provider Elevate Now.

Reuters 3 days ago

LLY

NVO
Tap Into the Silver Economy Boom With These Aging Demographics Stocks

The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.

Zacks 3 days ago

EXAS

NVO
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Pfizer bows, but is not entirely out of the GLP-1 race.

Motley Fool 3 days ago

NVO

VKTX

LLY

Performance Overview

Return	NOV.MU	OMX Copenhagen 25 Index (^OMXC25)
YTD	-29.58%	-14.74%
1-Year	-47.84%	-19.72%
3-Year	+35.24%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NOV.MU)

How Eli Lilly's GLP-1 pill could transform the weight-loss space

Eli Lilly stock soars on positive weight-loss pill results

Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill

Novo Nordisk downgraded by BMO as Eli Lilly gains ground in weight-loss drug race

Novo Nordisk Stock Drops on Eli Lilly Oral Weight-Loss Drug Success, Downgrade

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Novo Nordisk shares slump following Eli Lilly’s weight-loss pill success

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch

“I Am a Buyer”: Jim Cramer Backs Novo Nordisk (NVO) After Its Sharp Decline

Novo Nordisk A/S (NVO): A Bull Case Theory

The GLP-1 drug shortage is over. What’s next for the compounders?

Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?

Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts

Is Novo Nordisk A/S (NVO) the Best Pharma Stock to Buy for Long Term Growth?

Pfizer Halts Obesity Pill Development Amid Safety Concerns

Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries

Tap Into the Silver Economy Boom With These Aging Demographics Stocks

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Performance Overview